<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02336724</url>
  </required_header>
  <id_info>
    <org_study_id>FMTN-II-GIST</org_study_id>
    <nct_id>NCT02336724</nct_id>
  </id_info>
  <brief_title>A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor</brief_title>
  <official_title>A Single Arm, Open Label, Multicenter, Phase II Study of Famitinib in Patients With Gastrointestinal Stromal Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and&#xD;
      Flt3. Phase I study has shown that the toxicity is manageable.&#xD;
&#xD;
      The purpose of this study is to evaluate the efficacy and safety profile of Famitinib in&#xD;
      patients with advanced or metastatic gastrointestinal stromal tumor who failed from imatinib&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>96 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <arm_group>
    <arm_group_label>Famitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg qd p.o.,28 days as one cycle,treatment discontinued when disease progression determined or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famitinib</intervention_name>
    <arm_group_label>Famitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unresectable advanced or metastatic, histologically-confirmed, gastrointestinal&#xD;
             stromal tumor.Patients has been failed from last imatinib treatment due to disease&#xD;
             progression or unacceptable toxicity and unable to use sunitinib.&#xD;
&#xD;
          -  At least 2 weeks since the last imatinib administration&#xD;
&#xD;
          -  Must have at least one measurable disease by RECIST1.1 criteria(tumour lesions ≥10mm&#xD;
             in longest diameter, malignant lymph nodes ≥15mm in short axis, scanning layer ≤ 5&#xD;
             mm).&#xD;
&#xD;
          -  ECOG Performance status 0-1&#xD;
&#xD;
          -  Participants have adequate organ and marrow function as defined below:&#xD;
&#xD;
        neutrophils ≥ 1.5×10^9/L, platelets≥ 80×10^9/L, hemoglobin≥ 90g/L （no blood transfusion&#xD;
        within 14 days), serum transaminase(ALT and AST ) ≤ 2.5×ULN (If liver metastases are&#xD;
        present, serum transaminase≤5×ULN), total bilirubin ≤ 1.25×ULN, cholesterol ≤ 7.75mmol/L&#xD;
        and triglyceride≤1 x ULN, creatinine ≤1x ULN,creatinine clearance rate &gt; 50ml/min Urine&#xD;
        protein ≥ + + and confirmed the 24-hour urinary protein&gt;1.0 g normal serum calcium,&#xD;
        potassium,magnesium, phosphorus INR≤1.5 and APTT≤1.5 ULN LVEF: ≥ 50%&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with tyrosine kinase -inhibitor agent targeting at VEGFR, PDGFR and&#xD;
             c-Kit&#xD;
&#xD;
          -  The toxicity from previous imatinib or other treatment has not been recovered ≤ grade&#xD;
             1 according to CTCAE 3.0&#xD;
&#xD;
          -  Have surgery or radiotherapy within 4 weeks or have temporary radiotherapy for&#xD;
             palliative treatment within 2 weeks&#xD;
&#xD;
          -  A variety of factors that affect the oral medication (such as inability to swallow,&#xD;
             gastrointestinal resection, chronic diarrhea and intestinal obstruction)&#xD;
&#xD;
          -  Other cancer diagnosed within past 5 years or currently suffering , but other than&#xD;
             cure basal cell carcinoma and cervical carcinoma in situ&#xD;
&#xD;
          -  Within 12 months before the first treatment occurs artery / venous thromboembolic&#xD;
             events, such as cerebral vascular accident (including transient ischemic attack), deep&#xD;
             vein thrombosis and pulmonary embolism, etc&#xD;
&#xD;
          -  Uncontrollable thyroid dysfunction, even using medical therapy&#xD;
&#xD;
          -  Preexisting arrhythmia (including QT interval ≥ 450ms for male and 470ms for female)&#xD;
             and ≥ grade I heart failure&#xD;
&#xD;
          -  Patients with uncontrollable hypertension after using single agent therapy (systolic&#xD;
             blood pressure&gt; 140 mmHg, diastolic blood pressure&gt; 90 mmHg).&#xD;
&#xD;
          -  Known acute or chronic active hepatitis&#xD;
&#xD;
          -  Immunodeficiency: HIV positive, or other acquired immunodeficiency, congenital&#xD;
             immunodeficiency, or organ transplantation&#xD;
&#xD;
          -  Less than 4 weeks from the last clinical trial&#xD;
&#xD;
          -  Child bearing or pregnancy female. Potential child bearing female must have a negative&#xD;
             urine or serum pregnancy test result before initiating.&#xD;
&#xD;
          -  All subjects who are not surgically sterile or postmenopausal must agree and commit to&#xD;
             the use of a reliable method of birth control for the duration of the study and for 6&#xD;
             months after the last dose of test drug.&#xD;
&#xD;
          -  Evidence of significant medical illness that in the investigator's judgment will&#xD;
             substantially increase the risk associated with the subject's participation in and&#xD;
             completion of the study.&#xD;
&#xD;
          -  Mental disorders history, or Psychotropic drug abuse history&#xD;
&#xD;
          -  Abuse of Psychiatric drugs or dysphrenia&#xD;
&#xD;
          -  Other reasons from investigators' judgement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nanjing Bayi Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastrointestinal stromal tumor</keyword>
  <keyword>famitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

